Effect | Decrease |
Trial Design | Double blind |
Trial Length | 1-6 months |
Number of Subjects | 144 |
Sex | Both Genders |
Age Range | 18-29, 30-44, 45-64, 65+ |
Effect size from baseline to endpoint was moderate to large for SAMe versus placebo (d=0.74). SAMe was superior to escitalopram during weeks 2-6 but not 8-12, as escitalopram response was slow but caught up with SAMe late in the trial. Final response rates (HAMD-17≥50% reduction) were 45%, 31%, and 26% for SAMe, escitalopram, and placebo, respectively. Remission rates (HAM-D≤7) were 34% for SAMe (p=0.003), 23% for escitalopram (p=0.023), and 6% for placebo.